The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
Dr Severin Schwan was re-elected as Chairman of the Board with 97.75% of the votes
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The revenues this quarter are in line with the outlook we envisaged for the year
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Subscribe To Our Newsletter & Stay Updated
